Browse by author
Lookup NU author(s): Dr Alistair BrownORCiD, Dr Darren Smith
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
© 2016 Elsevier Masson SAS The neuroleptic drug thioridazine has been recently repositioned as possible anti-tubercular drug. Thioridazine showed anti-tubercular activity against drug resistant mycobacteria but it is endowed with adverse side effects. A small library of thioridazine derivatives has been designed through the replacement of the piperidine and phenothiazine moieties, with the aim to improve the anti-tubercular activity and to reduce the cytotoxic effects. Among the resulting compounds, the indole derivative 12e showed an antimycobacterial activity significantly better than thioridazine and a cytotoxicity 15-fold lower.
Author(s): Scalacci N, Brown AK, Pavan FR, Ribeiro CM, Manetti F, Bhakta S, Maitra A, Smith DL, Petricci E, Castagnolo D
Publication type: Article
Publication status: Published
Journal: European Journal of Medicinal Chemistry
Year: 2017
Volume: 127
Pages: 147-158
Print publication date: 15/02/2017
Online publication date: 23/12/2016
Acceptance date: 21/12/2016
Date deposited: 26/06/2018
ISSN (print): 0223-5234
ISSN (electronic): 1768-3254
Publisher: Elsevier Masson SAS
URL: https://doi.org/10.1016/j.ejmech.2016.12.042
DOI: 10.1016/j.ejmech.2016.12.042
PubMed id: 28039773
Altmetrics provided by Altmetric